PURPOSE: To study the effect of unperturbed tumor growth on the control of nasopharyngeal carcinoma. METHODS AND MATERIALS: This is a retrospective analysis of 290 patients with T1N0-3M0 disease (Ho's classification) treated by the same technique and dose schedule to the nasopharyngeal region. The median interval from diagnosis to commencement of irradiation was 26 days (range: 8-68 days). Cox proportional hazards analyses were performed to study the independent effect of waiting time on the probability of failure at various sites. Actuarial failure-free survival of patients with delay < 22 days, 22-28 days and > 28 days were also compared to illustrate the clinical observation. RESULTS: Both tests showed that waiting time had no significant impact on local failure: The N-stage stratified hazard ratio was 0.985 per day, and the 10-year local failure-free survival for the three groups was 76%, 80%, and 82%, respectively. A similar result was obtained for nodal control in patients with our scheduled neck irradiation. Although the p value of all tests failed to reach statistical significance, the N-stage stratified hazard ratio for distant failure was 1.020 per day, and the corresponding metastasis-free survival in patients with N2-3 disease was 70%, 65%, and 52%, respectively. For node-negative patients without elective neck irradiation, the hazard ratio was 1.019 per day, with the corresponding regional failure-free rates at 57%, 62%, and 33%, respectively. CONCLUSION: Delay in initiation of treatment to the primary target (within the range observed) did not affect the control rate at irradiated sites, but there was a trend (though statistically insignificant) towards increase in failures at untreated sites that were clinically too serious to be ignored.
PURPOSE: To study the effect of unperturbed tumor growth on the control of nasopharyngeal carcinoma. METHODS AND MATERIALS: This is a retrospective analysis of 290 patients with T1N0-3M0 disease (Ho's classification) treated by the same technique and dose schedule to the nasopharyngeal region. The median interval from diagnosis to commencement of irradiation was 26 days (range: 8-68 days). Cox proportional hazards analyses were performed to study the independent effect of waiting time on the probability of failure at various sites. Actuarial failure-free survival of patients with delay < 22 days, 22-28 days and > 28 days were also compared to illustrate the clinical observation. RESULTS: Both tests showed that waiting time had no significant impact on local failure: The N-stage stratified hazard ratio was 0.985 per day, and the 10-year local failure-free survival for the three groups was 76%, 80%, and 82%, respectively. A similar result was obtained for nodal control in patients with our scheduled neck irradiation. Although the p value of all tests failed to reach statistical significance, the N-stage stratified hazard ratio for distant failure was 1.020 per day, and the corresponding metastasis-free survival in patients with N2-3 disease was 70%, 65%, and 52%, respectively. For node-negative patients without elective neck irradiation, the hazard ratio was 1.019 per day, with the corresponding regional failure-free rates at 57%, 62%, and 33%, respectively. CONCLUSION: Delay in initiation of treatment to the primary target (within the range observed) did not affect the control rate at irradiated sites, but there was a trend (though statistically insignificant) towards increase in failures at untreated sites that were clinically too serious to be ignored.
Authors: Georges Noel; Aymeri Huchet; Loic Feuvret; Jean Philippe Maire; Pierre Verrelle; Emilie Le Rhun; Maud Aumont; François Thillays; Marie Pierre Sunyach; Chantal Henzen; Fernand Missohou; Renaud de Crevoisier; Pierre Yves Bondiau; Philippe Collin; Xavier Durando; Gilles Truc; Christine Kerr; Valérie Bernier; Jean-Baptiste Clavier; David Atlani; Anne D'Hombres; Sandrine Vinchon-Petit; Jean Léon Lagrange; Luc Taillandier Journal: J Neurooncol Date: 2012-06-02 Impact factor: 4.130
Authors: Luke H DeGraaff; Alexis J Platek; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni Abraham Kuriakose; Wesley L Hicks; Mary E Platek; Anurag K Singh Journal: Oral Oncol Date: 2019-07-30 Impact factor: 5.337
Authors: Sören Dahlke; Diana Steinmann; Hans Christiansen; Martin Durisin; Andre Eckardt; Gerd Wegener; Michael Bremer; Andreas Meyer Journal: In Vivo Date: 2017 Sep-Oct Impact factor: 2.155
Authors: Deborah T Blumenthal; Minhee Won; Minesh P Mehta; Walter J Curran; Luis Souhami; Jeff M Michalski; C Leland Rogers; Benjamin W Corn Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Karolina Osowiecka; Monika Rucinska; Jacek J Nowakowski; Sergiusz Nawrocki Journal: Int J Environ Res Public Health Date: 2018-03-23 Impact factor: 3.390